Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

8.14
-0.2900-3.44%
Post-market: 8.140.00000.00%16:37 EDT
Volume:10.42M
Turnover:85.07M
Market Cap:3.69B
PE:-11.53
High:8.42
Open:8.32
Low:8.04
Close:8.43
52wk High:9.36
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:0.92
T/O Rate:2.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:5.01
PE(LYR):-7.44

Loading ...

Iovance receives Australian approval of Amtagvi for advanced melanoma

TIPRANKS
·
Jun 04

Australia TGA approves Iovance Amtagvi for previously treated advanced melanoma

Reuters
·
Jun 04

Iovance’s Amtagvi® (Lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

THOMSON REUTERS
·
Jun 04

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

GlobeNewswire
·
Jun 04

Iovance gets allowance to proceed from FDA for IOV-5001 IND application

TIPRANKS
·
Jun 01

Iovance Biotherapeutics Receives US FDA Clearance to Begin IOV-5001 Trial in Solid Tumors

MT Newswires Live
·
Jun 01

Iovance says FDA clears IND for IL-12 tethered TIL therapy IOV-5001

Reuters
·
Jun 01

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (Ind) Application for Il-12 Tethered Til Therapy Iov-5001

THOMSON REUTERS
·
Jun 01

A Look At Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Recovery

Simply Wall St.
·
May 31

Iovance grants inducement stock options for 93,340 shares at $3.7 each

Reuters
·
May 23

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
May 23

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Black Diamond Therapeutics (BDTX) and Iovance Biotherapeutics (IOVA)

TIPRANKS
·
May 22

Can Iovance (IOVA) Turn Early Amtagvi Data and Manufacturing Tweaks into a Durable Advantage?

Simply Wall St.
·
May 22

Iovance Biotherapeutics to Present at Upcoming Conference

GlobeNewswire
·
May 21

What Iovance Biotherapeutics (IOVA)'s Amtagvi Momentum and Narrowing Losses Means For Shareholders

Simply Wall St.
·
May 15

Iovance Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
May 08

Iovance Biotherapeutics price target lowered to $14 from $16 at Chardan

TIPRANKS
·
May 08

BUZZ-U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise

Reuters
·
May 08

Sector Update: Health Care

MT Newswires Live
·
May 08

BUZZ-Iovance Biotherapeutics falls on Q1 revenue miss

Reuters
·
May 07